Autres langues Pfizer Inc.

Actions

PFE

US7170811035

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 19:15:33 22/07/2026			Varia. 5j.	Varia. 1 janv.
24,94 ^USD	-0,02%		+0,46%	+0,14%

17/07	Bourse : Dassault à l'achat, SpaceX à quai, Netflix dans les choux
17/07	Sale semaine pour les valeurs préférées du marché

Autres langues

21/07	Enanta Was First To File. Pfizer Still Won. The Difference Was One Digit.
20/07	Pfizer Inc. Submits Notification of Proposed Production Activity to Ftz Board for Facilities in Kalamazoo and Portage, Michigan
17/07	Afternoon Meeting: El cheque en blanco a la IA empieza a cuestionarse
17/07	AI's Blank Check Is Bouncing
17/07	Federal Circuit Decision: When A Typo Costs A Patent Its Priority Date
17/07	A Tough Week for the Market's Favourite Stocks
17/07	Morning Meeting: Eine harte Woche für die Lieblingsaktien des Marktes
16/07	Federal Circuit: Provisional Application Must Support Later Claims
16/07	Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
16/07	Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech -- Update
16/07	Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech
16/07	Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents
16/07	AM Best Affirms Credit Ratings of Blue Whale Re Ltd
15/07	Celcuity shares fall as launch delay eclipses US approval for breast cancer drug
15/07	Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
14/07	US FDA approves Celcuity's breast cancer drug
13/07	“2” Does Not Provide Written Description Support For “1”: Federal Circuit Affirms District Court’s Invalidation Of Patent
13/07	Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug
10/07	Health Care Down on Rotation Back to Tech - Health Care Roundup
10/07	Merck, Pfizer, Astellas Bladder Cancer Treatment Approved by FDA
10/07	Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says
10/07	Pfizer Poised for Mixed Second Quarter, RBC Says
10/07	Pfizer : U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin EligibilityPrescription MedicinesMedicines
10/07	U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
10/07	Pfizer Inc. and Astellas Pharma Inc. Receive U.S. FDA Approval for PADCEV Plus Keytruda as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer